Alphamab Oncology (HKSE:09966) Accounts Payable & Accrued Expense : HK$69.5 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Accounts Payable & Accrued Expense?

Alphamab Oncology's quarterly accounts payable & accrued expense declined from Dec. 2023 (HK$65.4 Mil) to Jun. 2024 (HK$47.6 Mil) but then increased from Jun. 2024 (HK$47.6 Mil) to Dec. 2024 (HK$69.5 Mil).

Alphamab Oncology's annual accounts payable & accrued expense increased from Dec. 2022 (HK$52.1 Mil) to Dec. 2023 (HK$65.4 Mil) and increased from Dec. 2023 (HK$65.4 Mil) to Dec. 2024 (HK$69.5 Mil).

Alphamab Oncology Accounts Payable & Accrued Expense Historical Data

The historical data trend for Alphamab Oncology's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Accounts Payable & Accrued Expense Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

57.30

71.91

52.13

65.38

69.48

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial										52.13	47.71	65.38	47.60	69.48

Alphamab Oncology Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Alphamab Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its products pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Executives

South Dakota Trust Company Llc	2301 Trustee
Xu Ting	2305 Beneficiary of a trust
Liu Yang	2307 Founder of a discretionary trust who can infl
Rubymab Ltd.	2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology Headlines

No Headlines